Tiziana Life Sciences reported fresh Phase 2 readout data for its intranasal CD3-targeting monoclonal antibody Ferralumab in secondary progressive multiple sclerosis. The company said it uses an intranasal delivery approach intended to accumulate in cervical lymph nodes, where it drives regulatory T-cell activity that crosses the blood-brain barrier to modulate activated microglia. Tiziana positioned secondary progressive MS as a setting with limited approved options, in contrast to earlier-stage or relapsing MS where different disease-modifying therapies can be used. The company’s update frames the mechanism around converting activated microglia toward a more homeostatic state to reduce neuroinflammation. For clinicians and trial planners, the messaging emphasizes how route-of-administration and immune-cell biology are being used together to address refractory progressive disease.